SciGen partner increases investment
Friday, 04 November, 2005
The two largest shareholders in Singapore-based, ASX-listed biopharmaceutical company SciGen (ASX:SIE), SciTech Medical and Bioton, have entered into a share exchange agreement which may result in Bioton gaining a 44.7 per cent equity share in SciGen.
Under the agreement between Polish company Bioton and Singapore private healthcare company SciTech, Bioton will invest AUD$30 million to accelerate the launch of SciGen's portfolio of biopharmaceutical products to market.
SciTech is selling its shares to Bioton for $0.075 per SciGen share, a premium to the ASX market price of $0.067 at close of trading on Friday 28 October when the deal was entered into.
Saul Mashaal will remain as SciGen's executive vice-chairman and CEO, and will be elected to the supervisory board of Bioton.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
